New drugs for BNCT: An experimental approach

New kinds of boron-containing drugs were developed and tested in several mu rine tumor models. The boron-containing ether lipid B-Et-11-OMe was injecte d in mammary carcinoma (AT17) and osteosarcoma (OTS-64) bearing mice. Furth ermore boron-substituted ferrocenium derivatives were tested. Two were exce ssively toxic; the third could be investigated. Boron accumulation and time -dependent biodistribution were determined using alpha-particle sensitive f ilms and inductively coupled plasma-atomic emission pectrometry (ICP-AES) a nd -mass spectrometry (ICP-MS) of tumors, organs and tissues. Additionally, a new method of boron detection by NMR is in preparation.